Assessing the progression of Alzheimer’s Disease in real-world settings in three European countries

Manuscript Number: 

20-1172R2

Author(s): 
Baishali M. Ambegaonkar, Christopher M. Black, Farid Chekani, Lutz Frölich, Rezaul K. Khandker, Nuria Lara, Albert Lladó, Montse Roset

Disclosures

Baishali M. Ambegaonkar

  • Equity:
    Merck & Co., Inc.
    Sponsors:
    Merck & Co., Inc.

Christopher M. Black

  • Equity:
    Merck & Co., Inc.
    Sponsors:
    Employee of Merck & Co., Inc.

Farid Chekani

  • Sponsors:
    Merck & Co., Inc., Kenilworth, NJ, USA

Lutz Frölich

  • Consulting Fees:
    Consulting fees: Abbott, Allergan, Axon Neuroscience, Biogen, Eisai, InfectoPharm, MerckSharpe & Dohme, Novo Nordisk, Roche, Schwabe Pharma
    Lecture Fees:
    Lecture fees: Eisai, Roche, Schwabe Pharma

Rezaul K. Khandker

  • Equity:
    As Merck employee, receive stock offering as part of remuneration
    Sponsors:
    Employee at Merck

Nuria Lara

  • Nothing to Disclose

Albert Lladó

  • Consulting Fees:
    I received consulting fees from MSD in 2019

Montse Roset

  • Nothing to Disclose